Salmon-Ceron D, Mazeron MC, Boukli N, Houhou N, Chaput S, Senechal B, Imbert BM, Scieux C, Bour JM, Palmer P, Deny P, Katlama C, Costagliola D; Interscience Conference on Antimicrobial Agents and Chemotherapy.
Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 1998 Sep 24-27; 38: 449 (abstract no. I-272).
Dijon Hospitals, Paris, France.
In the context of HAART, the natural history of CMV disease has changed and a study was undertaken to investigate current risk factors for CMV disease. 200 pts with CD4 cell count <100/mm3 or < 200/mm3 under protease inhibitors (PI) for at least 2 months, were followed each 4 months clinically, for HIV RNA and CMV blood markers (blood culture, pp65 antigenemia, mRNA PCR, plasmatic DNA-PCR (Amplicor, Roche Molecular Systems). At inclusion, median CD4 was 77/mm3 and 85% pts received PI. After a median follow-up of 12 months, the incidence of CMV disease was 5.3 pt-years. In a Cox model, the Hazard Ratios (HR) of CMV disease were: (Table: see text) In conclusion, plasma DNA PCR was the main predictive factor of CMV disease, detected a median of 65 days before diagnosis. Our results strongly suggest that plasma CMV DNA is a valuable decision marker for initiating CMV therapy, which should be evaluated in clinical trials.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Antiretroviral Therapy, Highly Active
- CD4 Lymphocyte Count
- HIV Infections
- HIV Seropositivity
- Humans
- Incidence
- Risk Factors
Other ID:
UI: 102188434
From Meeting Abstracts